AbstralTM continues strong development of over 40 percent in first-quarter 2010 Orexo Stomach today confirms that its partner, ProStrakan Group plc has announced that AbstralTM continues to show strong sales development this year 2010.8 million in its first year in the marketplace.0 million. The successful establishment in each one of the countries in which it’s been launched is certainly demonstrated by the following market shares : France 27 percent; Germany 20 percent; Spain 10 percent; Sweden 69 percent; and UK 21 percent. There is also evidence of a significant upsurge in the size of the marketplace for fentanyl-based items for breakthrough cancer discomfort across the major EU-countries where ProStrakan operates .Excluding the effect of the noticeable change in U.S. Influenza revenues and the impact on revenues from the U.S. Meter-based Triage product sales, currency adjusted organic growth inside our Professional Diagnostics segment was bad 1 percent. This growth rate was adversely impacted by the reduction in reimbursement rates that became effective on July 1, 2013 for our U.S. Mail-order diabetes business. Excluding revenues from our U.S. Mail-order diabetes business and considering the Triage and flu changes, the currency modified organic development rate for the 1st one fourth of 2014 was 4 percent for the rest of our Professional Diagnostics segment. The 4 percent modified organic growth rate for our Professional Diagnostic segment for the first quarter of 2014, adjusted for the influence of the U.S.